Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular ... major cardiovascular events, with significant benefits already evident by the first 6 months, and for some ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular ... major cardiovascular events, with significant benefits already evident by the first six months, and for some ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

GLP-1 stands for glucagon-like peptide-1, a satiety hormone the body produces when we eat to help stimulate digestion and ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

In SELECT, semaglutide showed a 20% reduction in major adverse cardiovascular events (MACE) – including cardiovascular death, non-fatal heart attack, or non-fatal stroke – with the benefits ...